Vicadrostat

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Heart FailureChronic Kidney DiseaseCardiovascular DiseaseDiabetes Mellitus, Type 2

687 competitors in Heart Failure

#DrugCompanyPhaseTrials

1

Vicadrostat

Boehringer Ingelheim

Phase 3

22

Brethine

Sanofi

Preclinical

13

Medrol

Pfizer

Preclinical

14

LCZ696

Novartis

Preclinical

155

Activase

Roche

Preclinical

—6

Zemplar

AbbVie

Preclinical

—7

Coumadin

AAbbott

Preclinical

18

GLP-1

RRigshospitalet, Denmark

Preclinical

29

Antidiabetic

FFederico II University

Preclinical

110

Iron Sulphate

PPierre Fabre Pharma GmbH

Preclinical

1Show 10 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Empagliflozin2 trials

A Study in Healthy Men to Compare the Amount of Vicadrostat and Empagliflozin in the Blood When Taken Separately and Together

Completed·Boehringer Ingelheim·Phase 1·NCT07035457·15 enrolled

A Study in Healthy People to Test How 2 Different Formulations of a Combination Treatment (Vicadrostat and Empagliflozin) Are Taken up in the Body and How Food Influences the Amount of the Medicines in the Blood

Completed·Boehringer Ingelheim·Phase 1·NCT07133399·32 enrolled

Heart Failure2 trials

EASi-HF Reduced - A Phase III Double-blind, Randomised, Parallel-group Superiority Trial to Evaluate Efficacy and Safety of the Combined Use of Oral Vicadrostat (BI 690517) and Empagliflozin Compared With Placebo and Empagliflozin in Participants With Symptomatic Chronic Heart Failure (HF: NYHA II-IV) and Left Ventricular Ejection Fraction (LVEF) < 40%

Recruiting·Boehringer Ingelheim·Phase 3·NCT06935370·4,200 enrolled

EASi-HF Preserved - A Phase III Double-blind, Randomised, Parallel-group Superiority Trial to Evaluate Efficacy and Safety of the Combined Use of Oral Vicadrostat (BI 690517) and Empagliflozin Compared With Placebo and Empagliflozin in Participants With Symptomatic Heart Failure (HF: NYHA II-IV) and Left Ventricular Ejection Fraction (LVEF) ≥40%

Recruiting·Boehringer Ingelheim·Phase 3·NCT06424288·6,000 enrolled

Spironolactone1 trial

Comparative Study on the Mode of Action of Vicadrostat and Spironolactone on Protein Profiles and Renal Hemodynamic Effects (COMPARE-VS)

Not yet recruiting·UUniversity Medical Center Groningen·Phase 2·NCT07304817·100 enrolled

Diabetes Mellitus, Type 21 trial

EASi-PROTKT™ - A Phase III Double-blind, Randomised, Parallel-group Superiority Trial to Evaluate Efficacy and Safety of the Combined Use of Oral Vicadrostat (BI 690517) and Empagliflozin Compared With Placebo and Empagliflozin in Participants With Type 2 Diabetes, Hypertension and Established Cardiovascular Disease

Recruiting·Boehringer Ingelheim·Phase 3·NCT07064473·11,800 enrolled

Chronic Kidney Disease1 trial

A Phase II Randomised, Double-blind, Parallel-group, Multicentre, International Trial to Investigate the Safety and Efficacy of Vicadrostat and Empagliflozin Administered With Simultaneous vs Staggered Initiation in Participants With Chronic Kidney Disease at Risk of Kidney Disease Progression

Active, not recruiting·Boehringer Ingelheim·Phase 2·NCT06926660·492 enrolled

1 more indication

Unspecified1 trial

Thorough QT Study to Evaluate the Effects of Single Doses of Vicadrostat on Cardiac Safety Parameters in Healthy Male and Female Subjects (a Randomized, Placebo-controlled, Double-blind, Five-period Crossover Study With Open-label Moxifloxacin as Positive Control)

Active, not recruiting·Boehringer Ingelheim·Phase 1·NCT07513207·45 enrolled

Details

Drug Info

Related News